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The progressive enhancements in short term organ allograft survival have largely been attributed to 
improved surgical and post-operative care and the advent of more effective immunosuppressive 
agents. However, despite these encouraging observations, the high incidence of delayed graft loss 
due largely to transplant vascular sclerosis (TVS) and the presence of overt complications 
associated with the use of nonspecific immunosuppression (IS) remain unacceptable. It has been 
estimated that the incidence of TVS in allografts that have survived more than five years is up to 
43%, 50% and 60% in recipients of kidneys (1), lungs (2) and hearts (3) respectively. 
Conversely, its prevalence is markedly lower (3.6-16.8%) in long-surviving liver allograft 
recipients (4). These observations compounded by the fact that once established, histopathological 
changes characteristic of chronic rejection (CR) are irreversible and somewhat refractory to 
exogenous intervention, has necessitated the urgent development of therapeutic strategies that 
would allow for its attenuation and/or abrogation. 
ETIOPATHOLOGY OF TRANSPLANT VASCULAR SCLEROSIS 
While the factors that underlie the changes pathognomonic of (CR) are poorly understood, the 
etiology nevertheless appears to be multifactorial (Table 1; 5). 
a) Non-Immune Factors: 
The direct detrimental influence of various immunosuppressive agents used to prevent acute 
cellular rejection (ACR), on the development of post-transplant vasculopathy has been extensively 
documented (6, 7). The virtually indistinguishable clinical and histological presentation of the 
signs and symptoms of drug-induced nephrotoxicity and post-transplant vasculopathy have further 
compounded this conundrum. The modest and often transient improvement in graft function 
witnessed following withdrawal of drugs in presumptive cyclosporin or tacrolimus-induced 
nephrotoxicity is reminiscent of observations considered diagnostic of evolving CR. Similarly, 
chronic use of steroids has also been implicated in mediating progressive glomerulopathy with 
consequent glomerular capillary hypertension; findings considered characteristic of developing CR. 
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The role of systemic infection in the evolvement of CR in long-surviving organ allografts has also 
been documented (8, 9). Study of the effects of cytomegalovirus (CMV) infection on graft 
arteriosclerosis in cardiac transplant recipients suggests that its presence greatly enhances 
myointimal thickening with a corresponding diminution in patient and graft survival (8). Similarly, 
herpes virus infection both in humans and in experimental animals has been shown to accelerate 
chronic atherosclerosis (9). While the precise mechanism underlying the virus-induced 
acceleration of vasculopathy is unknown, it is nevertheless postulated that viral infections may 
modify lipid metabolism within the cellular components of the vessel wall resulting in overt fat 
accumulation; an event which may further deteriorate the ongoing intimal thickening with its 
corresponding luminal narrowing (10). 
b) Immune Factors: 
Whilst the foregoing arguments concerning the etiopathology of CR may be bewildering, the role 
of alloimmune responses in the evolvement of this phenomenon is nevertheless incontrovertible 
(11). This latter dogma has been corroborated by numerous studies suggesting a lineal correlation 
between the intensity and the frequency of ACR and that of the severity and the incidence of 
development of post-transplant vasculopathy (12, 13). Excluding the precise nature of the effector 
mechanisms (to be discussed later), it has been postulated that repetitive immune-mediated 
endothelial cell injury in vascularized allografts results in progressive intimal proliferation and 
hypertrophy which eventually culminates in gradually worsening luminal obliteration. In 
allotransplanted hearts, the eventual consequence of this low-grade "endothelialitis" is diffuse 
concentric tapering of the conductance vessels and gradual pruning of the distal arterioles. The 
piecemeal involvement of the large coronary arteries and their terminal branches results in patchy 
myocardial infarction and progressive fibrosis. The latter morphological aberrations translate 
clinically into an inexorable decline in myocardial function leading to the development of 
congestive heart failure, silent myocardial infarction, sustained ventricular arrhythmia, sudden 
cardiac arrest and in a large percentage of patients, in retransplantation. 
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The degree of HLA matching and its ultimate influence on the development of CR remains a 
controversial issue. Nevertheless, the higher incidence of long-term graft survival in living-related 
as compared to that to recipients of cadaveric renal allografts suggests that HLA-matching and its 
salutary effects on ACR may playa role in the development of CR (14). The correlation between 
HLA-matching and the development of post-transplant arteriopathy is however, far more nebulous 
in clinical heart transplant recipients. There has been conflicting evidence which has undermined 
the role of HLA matching in the development of progressive coronary arteriosclerosis (15). 
TOLERANCE AND TRANSPLANT VASCULAR SCLEROSIS 
Perhaps the most convincing evidence for an immune etiology in the evolvement of CR is provided 
by the observation that prior induction of donor-specific tolerance has benignant effects on the 
subsequent development of post-transplant vasculopathy (11, 16-24). Demetris et at., (18, 19) 
have demonstrated the beneficial effects of donor cell chimerism-induced tolerance on CR in a 
vascularized model of heterotopic cardiac alloTx in rats. Using Lewis (RTl l ) .... Brown Norway 
(RT! 0) rat strain combination, they have demonstra.ted that prior donor-strain liver-induced 
transplantation tolerance protected the challenge donor but not third party heterotopic heart 
allografts from developing changes pathognomonic of CR. 
In a mouse model, we have also tested this tenet by transplanting aorta across a fully allogeneic 
strain (C57Bl/1O; H-2b-7C3H; H-2k), combination in which the recipient was rendered tolerant by 
prior transplantation of liver from donor-strain (Group III) mice (11). Aorta grafted in syngeneic 
(Group I; C3H-?C3H) and allogeneic (Group II, C57BlIl0-?C3H) animals served as controls. 
The recipients were not immunosuppressed. No morphological changes were evidenced in the 
transplanted aortas in Group I animals. Contrarily, aortic allografts in Group II animals underwent 
a self-limiting ACR which resolved completely and was succeeded by day 30 post-transplantation, 
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of histopathological changes pathognomonic of CR. There was evidence for diffuse myointimal 
thickening, progressive concentric luminal narrowing and patchy destruction of internal elastic 
membranes resulting in massive vascular obliteration by day 120 post-transplantation. 
Interestingly, no arteriosclerotic changes were observed for the duration of follow-up (upto 120 
days post-transplantation) in transplanted aortas (liver donor-type) harvested from animals in 
Group III (Figure 1, A, B & C). However, vasculopathy was prominent in third-party aortic 
grafts transplanted into tolerant recipients (Figure 1, D). These data suggest that prior induction of 
tolerance abrogates the development ofTVS and that this protection appears to be donor-specific. 
Studies in humans have also yielded encouraging observations (21-24). Keenan et aI., (21) have 
reported that the presence of microchimerism and the subsequent establishment of donor-specific 
hyporesponsiveness was invariably associated with lower incidence of obliterative bronchiolitis 
(OB) in lung allotransplant recipients. These findings have been further corroborated by 
Reinsmoen et al., (22) who showed that in lung allograft recipients who were 2.8-5 years post-
transplantation, no OB was evidenced in those exhibiting donor-specific hyporesponsiveness. 
Contrarily, 9/17 (53%) patients who were responsive to donor antigens in in vitro proliferative 
assays developed OB over a comparable period of follow-up (22). Similar observations have also 
been made in long-term renal allograft recipients (23). It is noteworthy that in our prospective 
clinical trial entailing concomitant perioperative donor BM infusion and organ alloTx, we have also 
documented the presence of increased incidence of OB in contemporaneously accrued non-
marrow-augmented lung transplant recipients as compared to that to the study (marrow-augmented) 
patients (24). 
MEDIATORS OF TRANSPLANT VASCULAR SCLEROSIS 
There are three distinct host immune responses which operate in concert to orchestrate the 
development of TVS. 
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a) Cellular Responses: The seminal role of infiltrating effector (mainly CD8+ T) cells in 
allograft rejection has been well documented. On the contrary, cellular infiltration in an established 
lesion of post-transplant vasculopathy is a relatively less prominent event (26). This latter 
assertion does not however, imply that cell-mediated immune responses do not play an important 
role in the generation of CR. On the contrary, in recipients of vascularized allografts, the primary 
insult to the vascular endothelium which triggers the cascade of events leading to the development 
of CR is envisioned to be mediated by cell-dependent cytotoxicity. It is interesting to note that 
regardless of the type of rejection and the degree of cellular infiltration, the phenotype of the latter 
population is generally comparable consisting primarily of T cells and macrophages (27). 
Immunohistochemical examination of chronically rejecting human cardiac allografts has revealed 
the presence of moderate-to-marked lymphocytic infiltration with associated endothelialitis (28). 
Additionally, the majority ofT cells in these lesions were of CD8+ phenotype which together with 
macrophages were primarily localized in the subendothelial space of the coronary vessels which 
most markedly exhibited changes characteristic of CR (28). This observation is very similar to that 
in lung allografts undergoing OB where the predominant infiltrating T cell population was that of 
the CD8+ phenotype (29). For reasons not yet evident, in chronically rejecting liver allografts, 
preeminent infiltration of macrophages rather than that of T cells has been observed. Given the 
importance of cell-mediated immunity in CR, it is no surprise that a myriad of attempts are being 
made to abrogate and/or mitigate ACR with the assumption that its benignant effects will eventually 
be translated to prevent and/or reverse the evolvement of post -transplant obliterative vasculopathy. 
In addition to that by previously alluded (see above) strategies of inducing donor-specific 
tolerance, the latter goal has also been achieved by blockade of molecular interactions considered 
obligatory for the generation of an efficient T and B cell-mediated effector response. For the 
generation of the optimal effector response, it has been postulated that at least two signals are 
required (30). Recognition of processed peptides on the surface of antigen presenting cells (APC) 
by the T cell receptor (TcR) represents the initial antigen-specific event leading to cognate 
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interaction. This recognition triggers the engagement of a series of accessory molecules, whose 
function is to stabilize the TcR-MHC interaction and to coordinate the responses of the interacting 
cells. Two ligand-receptor systems that exert profound influence(s) on the outcome of 
costimulatory interactions have been identified. The ligation of CD28 on the effector cells to B 7.1 
and B7.2 on the APC triggers the activated T cell to produce lymphokines and avoid apoptotic cell 
death and/or anergy (30). More recently, the demonstration of the expression of gp39 (CD40 
ligand; CD40L) on activated T cells and its function as a ligand for CD40 expressed on various 
APC has unveiled as yet, another dominant costimulatory pathway for T and B cell activation (30, 
31). 
The availability of a wide array of suitable reagents has converged the interest of many 
investigators towards blocking the regulated delivery of signal two by the CD281B7 and the 
CD40/gp39 costimulatory pathways and to ascertain its effect on allograft survival and on post-
transplant vasculopathy. In the realm of allotransplantation, the use of CTLA4-Ig (which binds to 
B 7.1 and B 7.2 cell surface molecules) to block signaling through CD281B7 pathway has been 
shown to enhance allograft survival and to prevent or else markedly reduce the evolvement of 
changes characteristic of post-transplant obliterative vasculopathy (32-36). Similarly, down-
regulation of signaling discretely through the CD40/CD40L costimulatory pathway by the use of 
anti-CD40L mAb has also been shown to prolong allograft survival with albeit little or no salutary 
effects on CR (16, 37, 38). Perhaps the most persuasive evidence for the role of costimulatory 
signaling in the evolvement of post-transplant arteriosclerosis was provided by Larsen et al., (16), 
who recently demonstrated that in a primary vascularized murine model of heterotopic cardiac 
allotransplantation, contemporaneous but not discrete blockade of CD281B7 and CD40/gp39 
pathway resulted in complete abrogation of CR. 
In the aortic model of allotransplantation, we have also tested the efficacy of costimulatory 
blockage in preventing the development of TVS (39). For this purpose, aortic allografts were 
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transplanted across C57BlIIOJ (H -2b) .... C3H (H -2k) strain combinations. Transient or more stable 
blockade of signaling through CD281B7 pathway was achieved by either a single (Group A; d2 
post-transplantation) or multiple (Group B; ten doses from d2 post-transplantation and every 72h 
thereafter) injection(s) of CTLA4-Ig fusion protein (200J..Lg/dose i.p.). Additionally, CD40/CD40L 
costimulation was blocked by anti-CD40L monoclonal antibody (Group C; 250J..Lg i.m. on dO, 2 
and 4 post-transplantation). To ascertain the effect of combined simultaneous inhibition of both 
CD281B7 and CD40/CD40L pathways on CR, the aortic allograft recipients were treated with 
either a single (Group D; d2 post-transplantation) or multiple (Group E; dO, 2 and 4; and Group F; 
10 doses from d2 post-transplantation and every 72h thereafter) doses of CTLA4-Ig (200J..Lg i.p.) 
and anti-CD40L monoclonal antibody (250J..Lg Lm.). Untreated (Group G) and recipients treated 
with irrelevant isotype-matched monoclonal antibody (Group H) served as controls. At d30 post-
transplantation, the grafts were harvested for histopathological and immunohistochemical 
examination. 
Similar to that of animals in Group G (Figure 2C), aortic allografts obtained from recipients treated 
with either CTLA4-Ig (Groups A & B) or anti-CD40L monoclonal antibody (Group C) alone 
exhibited marked narrowing of the lumen primarily due to concentric intimal thickening caused by 
proliferation of a-smooth muscle actin+ cells. Contemporaneous treatment however, with either a 
single (Group D) or multiple (Group E) injections of CTLA4-Ig and anti-CD40L monoclonal 
antibody resulted in marked diminution of intimal thickening which was largely patchy with 
residual evidence for endothelial denudation. Interestingly, concurrent prolonged inhibition of 
CD281B7 and CD40/CD40L pathways (Group F) resulted in complete abrogation of the 
development of post-transplant arteriopathy (Figure 2D) suggesting that a more stable disruption of 
signaling through costimulatory pathways may be required to obviate the development of this 
vasculopathy. 
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b) Humoral Responses: The presence of circulating antibodies against discrete HLA 
epitopes or else against graft-specific antigens has been shown to precipitate early or immediate 
rejection of the transplanted organ allografts (40, 41). Similarly, the role of anti-HLA and anti-
graft antibodies in the evolvement of CR has also been widely premised (26). In cardiac transplant 
recipients, the development of graft arteriosclerosis has been correlated with the presence of anti-
HLA antibodies (42). Additionally, Mohanakumar et al., (43) have demonstrated the presence of 
immunoglobulin and complement complexes within the loci of thickened intima in renal allograft 
recipients in whom late graft rejection was correlated with presensitization to HLA-DR antigens. 
Perhaps the most convincing evidence for the role of alloantibodies in the development of CR was 
provided by O'Connell et al., (44) who successfully reproduced the histological aberration 
pathognomonic of post-transplant vasculopathy by intra-arterial infusion of donor-specific antisera. 
What are the molecular targets for cell and antibody-mediated immunity? It is generally believed 
that donor MHC IT antigens are the major targets for an antibody-mediated immune response. On 
the contrary, it is the class I antigens which are considered the key molecular targets of T cell 
mediated cytotoxicity. Effector responses against non-MHC antigens as targets have also been 
implicated in the generation of CR. Anti-B cell antibodies have been identified in patients 
harboring chronically rejecting renal allografts (41) as well as in long-term heart recipients in 
whom the allografts were undergoing CR. In addition to anti-B cell antibodies, those directed 
against specific antigens of the endothelial cells, tubular basement membrane and other non-MHC 
graft-specific antigens have also been identified. 
c) Soluble Factors/Adhesion Molecules: Whilst cell and antibody-mediated immune 
responses playa cardinal role in initiating vascular injury, it is the soluble mediators released at the 
site of insult which are considered quintessential for the perpetuation of the cascade of events 
which eventually culminate in the establishment of changes pathognomonic of CR. Various factors 
including thromboxane A2, platelet-derived growth factor, leukotrienes, platelet activating factors, 
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tumor necrosis factor (TNF), IL-I and IFN-'Y have been documented to play either a direct or an 
indirect role in the evolvement of CR (26). Although once released, these factors instigate wide-
" 
ranging changes in the target tissue, they predominantly influe11ce macrophage and monocyte 
infiltration and smooth muscle and mesangial cell proliferation; events that ultimately lead to the 
development of graft arteriosclerosis. 
Additionally, the role of adhesion molecules in precise trafficking of effectors of cell-mediated 
immunity is also incontrovertible (45). Intercellular adhesion molecule-I, CD2 (lymphocyte 
function associated molecule-2; LFA-2) and LFA-3 which are expressed on the vascular 
endothelium play an important role in activated T cell and macrophage infiltration. These 
molecules, whose expression can be upregulated by numerous soluble mediators (e.g. TNF, IFN-
'Y, etc.), influence both the adhesion and trans-endothelial migration of effector cells thus, ensuring 
their optimal accumulation at the site of injury; events that presage the development of changes 
characteristic of chronic graft vasculopathy (26). It is anticipated that the precise understanding of 
the role of soluble mediators and the cell surface expressed adhesion molecules in the evolvement 
of CR will unravel as yet another accessible target whose interruption may help mitigate the 
development of post-transplant arteriosclerosis. 
DIRECT VERSUS INDIRECT ANTIGEN PRESENTATION 
The concept that different MHC cell surface molecules (class I and II) predominantly present either 
endogenously or exogenously generated peptides is well established (46, 47). In allograft 
recipients, this fundamental distinction by the APC is further compounded by the "origin" of the 
MHC molecules which are involved in presenting donor antigens to reactive T cells. It has been 
proposed that donor antigens can be presented to recipient's alloreactive T cells by two discrete 
pathways (Figure 3). Recipient's alloreactive T cells' engagement and subsequent response to 
allogeneic MHC molecules is referred to as "direct" antigen presentation (Figure 3A). On the 
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contrary, processing and presentation of allogeneic MHC molecules by recipient's APC and their 
subsequent presentation to self-MHC restricted all ore active T cells is termed "indirect" antigen 
presentation (Figure 3B) (48). Due to the presence at a much higher frequency of non-self MHC-
restricted alloreactive T cells, direct mode of alloantigen presentation is considered to be far more 
vigorous than that mediated by its indirect counterpart. In line with this argument, it has been 
suggested that the early ACR witnessed after transplantation of MHC-mismatched allografts is 
mediated primarily by the direct pathway, although evidence is emerging that the indirect mode of 
allorecognition may also playa role in this phenomenon (47-49). 
Which class of MHC molecules predominantly presents shed donor antigens is still a controversial 
issue. It could however be argued, that shed antigens would prevalently be processed by the 
exogenous pathway resulting in its presentation by recipient's MHC class II molecules to self-
MHC restricted CD4+ T cells (4, 7). One could therefore appreciate the heterogeneity of epitopes 
that will be engendered by the processing and indirect presentation predominantly of donor MHC 
molecules thus, providing an explication for the potential generation of a powerful rejection 
response even by the indirect mode of antigen presentation. In addition to other as yet undefined 
justifications, the observed intransigence of chronic allograft rejection and of that of the "indirect" 
mode of antigen presentation to exogenously administered immunosuppression has raised the 
possibility of the involvement of the latter process in the development of post-transplant 
vasculopathy (50, 51). Perhaps the most lucid evidence for the role of indirect pathway in CR 
emanated from the recently presented (XVlth Annual Meeting of the American Society of 
Transplant Physicians, May 10-14, 1997, Chicago, IL) and as yet unpublished work of Sayegh et 
ai., (52), who by using as donors, a congenic strain of WF rats [CWFIL LEW/Gut CRTnl which 
express the same major but different minor MHC antigens as LEW CRT11) recipients, argued that 
the allorecognition in this model would be restricted to that to indirect antigen presentation 
providing a unique opportunity to study its influence on CR. It is noteworthy that hearts 
heterotopic ally transplanted across congenic WF .... LEW rats developed changes pathognomonic of 
11 
CR which were abrogated by a single injection of CTLA4-Ig given at d2 post-transplantation. 
While these findings are important, it could nevertheless be argued that contrary to the authors' 
claim, the presentation of the minor MHC antigen in this model may have been mediated via the 
direct pathway of antigen presentation. Until this conundrum is resolved, it would be difficult if 
not impossible to decipher the role of indirect pathway in CR in this particular model. 
How does the indirect pathway of antigen presentation facilitate the evolvement of changes 
characteristic of CR? While the mechanism(s) are as yet largely indeterminate, it has however, 
been argued that generation of alloreactive self-MHC restricted CD4+ T cells by indirect mode of 
antigen presentation evokes predominantly a delayed type hypersensitivity (DTH) response with 
resultant recruitment and activation of macrophages and the generation of a chronic inflammatory 
response (Figure 4). Additionally, there is growing evidence that primed self-MHC restricted 
CD4+ T cells provide the appropriate help to B cells resulting in their generation of alloantibodies. 
Interestingly, both DTH-type responses and alloantibodies have been implicated as possible 
mediators of the afferent limb of the effector response culminating in the development of CR 
(Figure 4). 
CONCLUSION 
Considerable progress has been made in the last decade to further our understanding of the 
pathogenesis of TVS. Numerous therapeutic strategies have been reported which are known to 
prevent the onset and/or reversal of this lesion in preclinical models of CR. However, as yet no 
therapeutic intervention is available that would allow for successful prevention or reversal of 
vascular changes pathognomonic of CR in clinical organ transplant recipients. The progressive 
nature of this lesion and its profound detrimental impact on long-term patient and graft survival has 
mandated urgent evolvement of clinically applicable strategies that would mitigate and/or abrogate 
its development. It is towards the achievement of this latter objective that we believe all of our 
future endeavors should be converged. 
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Table 1: Factors Influencing the Pathogenesis of Chronic Rejection 
a) nonimmune: 
• ischemia-reperfusion injury 
• immunosuppressive drugs 
• donor age 
• systemic infections 
• cytomegalovirus 
• herpes virus 
• hyperlipidemia and hypercholesterolemia 
b) immune: 
• histoincompatibility 
• incidence and severity of acute cellular rejection 
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Figure Legends 
Figure 1: Aortic allografts harvested at d30 (A and B) and d 60 (C) post-transplantation across 
C57BlIlO-?C3H mouse strain combinations. The recipients were rendered tolerant 
by previous (at d -30) orthotopic transplantation of liver obtained from the donor-
strain animal. Aortic allografts obtained from third-party (BALB/c) animals (D) were 
used as controls. Unlike that into naive C3H recipients, no evidence of CR was 
witnessed in aortic allografts transplanted into those rendered tolerant (A, B and C). 
As is evident in Verhoeff-van Gieson (VVG)-stained sections (B and C), the aortic 
architecture is well preserved at d30 (B) and d60 (C) post-transplantation. 
Contrarily, at d30 post-transplantation, aortic allografts obtained from third-party 
donors (BALB/C) when transplanted into tolerant recipients exhibit changes 
pathognomonic of TVS (D). There was evidence for progressive intimal thickening 
(D; arrows) which was largely due to proliferation of alpha smooth muscle actin+ 
cells. Magnification xiOO (A and B); x400 (C and D); inset xlOOO. 
Figure 2: Aortic allografts harvested at d50 post-transplantation across syngeneic (C3H-?C3H) 
mouse strain combination (B) showed marked preservation of aortic morphology. 
There is no evidence of endothelial denudation (Bb) or disruption of the internal 
elastic membranes (Ba). Interestingly, this morphology appears very similar to that 
of native aorta (A). On the contrary, aortas harvested at d30 post-transplantation 
across untreated allogeneic (C57BlIlO-?C3H) mouse strain combination (C) 
exhibited marked intimal thickening with associated disruption of the internal elastic 
membranes; the intimal thickening was due to proliferation of alpha smooth muscle 
actin+ cells (C inset). Prolonged treatment (10 doses from d2 post-transplantation and 
every 72h thereafter) of the recipient with CTLA4-Ig (200 Ilg i.p.) and anti-CD40L 
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monoclonal antibody (250J..lg i.m.) resulted in complete abrogation of the 
development of changes characteristic ofTVS (D). Magnification xlOO CA, B and C); 
x200 (D); isets x400 (Aa, Ba and C); xlOOO (Ab and Bb). 
Figure 3: Direct CA) and indirect (B) pathways of presentation of donor antigens to recipient's 
alloreactive T cells. 
Figure 4: Putative mechanism(s) for the development of post-transplant vasculopathy by the 
"indirect" pathway of antigen presentation. 
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